Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Perseus Proteomics Inc. (4882.T)
JPY160.00
+4.00 (+2.56%)
JP JPX Healthcare Drug Manufacturers - General
Address
30-1 Nihonbashi Hakozakicho 103-0015
Tokyo, JP
Tokyo, JP
CEO
Takuya Yokokawa
Website
ppmx.com
IPO
2021-06-22
ISIN JP3836800007
Description
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY160.00
+4.00 (+2.56%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
538.2K
Beta
0.32
Float Shares
14.36M
Free Float %
97.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.02% | -10.84% | -21.98% | -24.90% | -39.46% | -20.61% | -58.77% | -31.44% | -79.10% | -79.10% | -79.10% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
160.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.91
Grey zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%+12.6% ★ Q1'26: -13.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+24.0% ★ Q1'26: +22.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%-534.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%-549.8% Q1'26: -529.5% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%— Q1'26: +230.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+4.5% Q1'26: +4.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Mar 2022 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. |
Mar 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
71.93M
est: 70.00M (+2.8%)
|
100.40M
est: 100.00M (+0.4%)
|
120.38M
est: 2.01B (-94.0%)
|
1.32B
1.32B – 1.32B
-34.6% YoY
|
120.00M
120.00M – 120.00M
-90.9% YoY
|
887.00M
887.00M – 887.00M
+639.2% YoY
|
150.00M
150.00M – 150.00M
-83.1% YoY
|
161.00M
161.00M – 161.00M
+7.3% YoY
|
| EBITDA |
-478.59M
est: -70.00M (-583.7%)
|
-891.46M
est: -100.00M (-791.5%)
|
-826.86M
est: -2.01B (+58.9%)
|
-1.32B
-1.32B – -1.32B
+34.6% YoY
|
-120.00M
-120.00M – -120.00M
+90.9% YoY
|
-887.00M
-887.00M – -887.00M
-639.2% YoY
|
-150.00M
-150.00M – -150.00M
+83.1% YoY
|
-161.00M
-161.00M – -161.00M
-7.3% YoY
|
| EBIT |
-481.54M
est: -70.00M (-587.9%)
|
-894.95M
est: -100.00M (-795.0%)
|
-829.70M
est: -2.01B (+58.7%)
|
-1.32B
-1.32B – -1.32B
+34.6% YoY
|
-120.00M
-120.00M – -120.00M
+90.9% YoY
|
-887.00M
-887.00M – -887.00M
-639.2% YoY
|
-150.00M
-150.00M – -150.00M
+83.1% YoY
|
-161.00M
-161.00M – -161.00M
-7.3% YoY
|
| Net Income |
-599.02M
est: -816.20M (+26.6%)
|
-1.10B
est: -1.39B (+20.3%)
|
-904.80M
est: 934.64M (-196.8%)
|
336.89M
336.89M – 336.89M
-64.0% YoY
|
-931.66M
-931.66M – -931.66M
-376.5% YoY
|
-198.26M
-198.26M – -198.26M
+78.7% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| SGA |
231.52M
est: 211.54M (+9.4%)
|
366.41M
est: 302.52M (+21.1%)
|
335.93M
est: 5.97B (-94.4%)
|
3.91B
3.91B – 3.91B
-34.6% YoY
|
356.57M
356.57M – 356.57M
-90.9% YoY
|
2.64B
2.64B – 2.64B
+639.2% YoY
|
445.71M
445.71M – 445.71M
-83.1% YoY
|
478.40M
478.40M – 478.40M
+7.3% YoY
|
| EPS |
-50.94
est: -57.20 (+10.9%)
|
-93.69
est: -97.10 (+3.5%)
|
-63.41
est: 62.70 (-201.1%)
|
22.60
22.60 – 22.60
-64.0% YoY
|
-62.50
-62.50 – -62.50
-376.5% YoY
|
-13.30
-13.30 – -13.30
+78.7% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Ownership data is not available for this company yet.
Executive team
Top executives
EBIT / Employee
-298.0K
Shares Outstanding
14.75M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hidenori Ishii | Executive Officer and Head of Research Planning & Clinical Development Dept. | — | — |
| Shinichi Suzukawa | Head of Administrative Dept, Executive Officer & Director | — | male |
| Shinji Hagiwara | Executive Officer, Head of R&D Dept., Head of Business Development Dept. and Director | — | male |
| Susumu Tanahashi | Executive Officer and Head of Business Development Dept. & Deputy Manager of Administrative Dept. | — | — |
| Tadashi Matsuura | Chief Technology Officer & Executive Officer | — | — |
| Takuya Yokokawa | President, Chief Executive Officer, Executive Officer & Chairman | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4882.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
